Deletion of the gene for adiponectin accelerates diabetic nephropathy in the Ins2 +/C96Y mouse

Diabetologia

Volumn 58, Issue 7, 2015, Pages 1668-1678

  Fang, Fei ^a   Bae, Eun Hui ^a,b   Hu, Amanda ^a   Liu, George C ^a   Zhou, Xiaohua ^a   Williams, Vanessa ^a   Maksimowski, Nicholas ^a   Lu, Catherine ^a   Konvalinka, Ana ^c   John, Rohan ^c   Scholey, James W ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Chonnam National University Medical School   (South Korea)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Adiponectin; Diabetic nephropathy; High glucose; Kidney hypertrophy

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; S6 KINASE; SMAD2 PROTEIN; SMAD3 PROTEIN; SUPEROXIDE; TRIACYLGLYCEROL; INS2 PROTEIN, MOUSE; INSULIN;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOLUMINESCENCE; COLORIMETRY; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE DELETION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY HYPERTROPHY; KIDNEY INJURY; KIDNEY MASS; KIDNEY PROXIMAL TUBULE; MACROPHAGE; MESANGIUM CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; WESTERN BLOTTING; WILD TYPE; ANIMAL; FIBROSIS; GENETICS; INFLAMMATION; KIDNEY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ADIPONECTIN; ANIMALS; DIABETIC NEPHROPATHIES; FIBROSIS; GENE DELETION; HUMANS; INFLAMMATION; INSULIN; KIDNEY; MESANGIAL CELLS; MICE; MICE, KNOCKOUT; NF-KAPPA B; OXIDATIVE STRESS;

EID: 84931568570     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3605-9     Document Type: Article

References (48)

1. Tang SC (2010) Diabetic nephropathy: a global and growing threat. Hong Kong Med J 16:244–245
2. Packham DK, Alves TP, Dwyer JP et al (2012) Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis 59:75–83
3. Eckardt KU, Coresh J, Devuyst O et al (2013) Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 382:158–169
4. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820
5. Sun YM, Su Y, Li J, Wang LF (2013) Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun 433:359–361
6. Wiecek A, Adamczak M, Chudek J (2007) Adiponectin—an adipokine with unique metabolic properties. Nephrol Dial Transplant 22:981–988
7. Shetty S, Kusminski C, Scherer P (2009) Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies. Trends Pharmacol Sci 30:234–239
8. Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295
9. Akingbemi BT (2013) Adiponectin receptors in energy homeostasis and obesity pathogenesis. Prog Mol Biol Transl Sci 114:317–342
10. Chou IP, Lin YY, Ding ST, Chen CY (2014) Adiponectin receptor 1 enhances fatty acid metabolism and cell survival in palmitate-treated HepG2 cells through the PI3 K/AKT pathway. Eur J Nutr 53:907–917
11. Kim JE, Song SE, Kim YW et al (2010) Adiponectin inhibits palmitate-induced apoptosis through suppression of reactive oxygen species in endothelial cells: involvement of cAMP/protein kinase A and AMP-activated protein kinase. J Endocrinol 207:35–44
12. Yamauchi T, Nio Y, Maki T et al (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332–339
13. Denzel MS, Scimia MC, Zumstein PM, Walsh K, Ruiz-Lozano P, Ranscht B (2010) T-cadherin is critical for adiponectin-mediated cardioprotection in mice. J Clin Invest 120:4342–4352
14. Yamauchi T, Kamon J, Waki H et al (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941–946
15. Ouchi N, Kihara S, Arita Y et al (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 102:1296–1301
16. Ouchi N, Ohishi M, Kihara S et al (2003) Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42:231–234
17. Sharma K, Ramachandrarao S, Qiu G et al (2008) Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118:1645–1656
18. Decleves AE, Mathew AV, Cunard R, Sharma K (2011) AMPK mediates the initiation of kidney disease induced by a high-fat diet. J Am Soc Nephrol 22:1846–1855
19. Liu GC, Oudit GY, Fang F, Zhou J, Scholey JW (2012) Angiotensin-(1-7)-induced activation of ERK1/2 is cAMP/protein kinase A-dependent in glomerular mesangial cells. Am J Physiol Ren Physiol 302:F784–F790
20. Fang F, Liu GC, Kim C, Yassa R, Zhou J, Scholey JW (2013) Adiponectin attenuates angiotensin II-induced oxidative stress in renal tubular cells through AMPK and cAMP-Epac signal transduction pathways. Am J Physiol Ren Physiol 304:F1366–F1374
21. Holland WL, Miller RA, Wang ZV et al (2011) Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat Med 17:55–63
22. Rakatzi I, Mueller H, Ritzeler O, Tennagels N, Eckel J (2004) Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 47:249–258
23. Okamoto Y, Kihara S, Ouchi N et al (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767–2770
24. Shibata R, Sato K, Pimentel DR et al (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 11:1096–1103
25. Cheng CF, Lian WS, Chen SH et al (2012) Protective effects of adiponectin against renal ischemia-reperfusion injury via prostacyclin-PPARα-heme oxygenase-1 signaling pathway. J Cell Physiol 227:239–249
26. Jin X, Chen J, Hu Z, Chan L, Wang Y (2013) Genetic deficiency of adiponectin protects against acute kidney injury. Kidney Int 83:604–614
27. Guo Z, Zhao Z (2007) Effect of N-acetylcysteine on plasma adiponectin and renal adiponectin receptors in streptozotocin-induced diabetic rats. Eur J Pharmacol 558:208–213
28. Tamura Y, Murayama T, Minami M, Matsubara T, Yokode M, Arai H (2012) Ezetimibe ameliorates early diabetic nephropathy in db/db mice. J Atheroscler Thromb 19:608–618
29. Qian Y, Feldman E, Pennathur S, Kretzler M, Brosius FC 3rd (2008) From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 57:1439–1445
30. Lieberthal W, Levine JS (2009) The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 20:2493–2502
31. Zhan JK, Wang YJ, Wang Y et al (2014) Adiponectin attenuates the osteoblastic differentiation of vascular smooth muscle cells through the AMPK/mTOR pathway. Exp Cell Res 323:352–358
32. Su YX, Deng HC, Zhang MX, Long J, Peng ZG (2012) Adiponectin inhibits PDGF-induced mesangial cell proliferation: regulation of mammalian target of rapamycin-mediated survival pathway by adenosine 5-monophosphate-activated protein kinase. Horm Metab Res 44:21–27
33. Liu X, Hubchak SC, Browne JA, Schnaper HW (2014) Epidermal growth factor inhibits transforming growth factor-β-induced fibrogenic differentiation marker expression through ERK activation. Cell Signal 26:2276–2283
34. Sharma K, Ziyadeh FN (1994) The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 266:F829–F842
35. Nakamaki S, Satoh H, Kudoh A, Hayashi Y, Hirai H, Watanabe T (2011) Adiponectin reduces proteinuria in streptozotocin-induced diabetic Wistar rats. Exp Biol Med (Maywood) 236:614–620
36. Ohashi K, Iwatani H, Kihara S et al (2007) Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol 27:1910–1917
37. Yang J, Lin SC, Chen G et al (2013) Adiponectin promotes monocyte-to-fibroblast transition in renal fibrosis. J Am Soc Nephrol 24:1644–1659
38. Duran-Salgado MB, Rubio-Guerra AF (2014) Diabetic nephropathy and inflammation. World J Diabetes 5:393–398
39. Kobashi C, Urakaze M, Kishida M et al (2005) Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 97:1245–1252
40. Krakoff J, Funahashi T, Stehouwer CD et al (2003) Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26:1745–1751
41. Badal SS, Danesh FR (2014) New insights into molecular mechanisms of diabetic kidney disease. Am J Kidney Dis 63:S63–S83
42. Essick EE, Ouchi N, Wilson RM et al (2011) Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling. Am J Physiol Heart Circ Physiol 301:H984–H993
43. Oudit GY, Liu GC, Zhong J et al (2010) Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59:529–538
44. Liu GC, Fang F, Zhou J et al (2012) Deletion of p47phox attenuates the progression of diabetic nephropathy and reduces the severity of diabetes in the Akita mouse. Diabetologia 55:2522–2532
45. Lo CS, Liu F, Shi Y et al (2012) Dual RAS blockade normalizes angiotensin-converting enzyme-2 expression and prevents hypertension and tubular apoptosis in Akita angiotensinogen-transgenic mice. Am J Physiol Ren Physiol 302:F840–F852
46. Schiffer M, Mundel P, Shaw AS, Bottinger EP (2004) A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J Biol Chem 279:37004–37012
47. Chodavarapu H, Grobe N, Somineni HK, Salem ES, Madhu M, Elased KM (2013) Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. PLoS One 8:e62833
48. Alter ML, Kretschmer A, von Websky K et al (2012) Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab 58:659–671